Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7768

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7768). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500907768)

Label Image (Lbl500907768)
Levetiracetam 500 mg film-coated tablets label from A-S Medication Solutions. The label shows the product name, dosage form, strength, package quantity of 120 tablets, storage instructions (store at 68 to 77 degrees Fahrenheit), and includes a QR code and NDC 50090-7768-0.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to treatments. The vertical axis shows percentage of patients from 0% to 45%. Three bars represent Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). An asterisk indicates statistically significant differences versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day treatments. The y-axis represents the percentage of patients (0% to 45%). Placebo shows a 6.3% responder rate, Levetiracetam 1000 mg/day 20.8%, and Levetiracetam 2000 mg/day 35.2%. Statistically significant differences versus placebo are indicated.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The graph shows 14.4% response for placebo (N=104) and 39.4% response for Levetiracetam 3000 mg/day (N=180), with an asterisk indicating statistical significance versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to placebo with those responding to Levetiracetam. The placebo group (N=97) shows a response rate of 19.6%, while the Levetiracetam group (N=101) shows a higher response rate of 44.6%, marked as statistically significant versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar graph depicting the responder rate for patients aged 1 month to under 4 years showing a 50% or greater reduction from baseline in Study 5. The y-axis represents the percentage of patients, with two bars comparing placebo (19.6%) and Levetiracetam (43.1%), indicating a higher responder rate in the Levetiracetam group with statistical significance noted.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
Bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' showing percentage of patients achieving response. The chart compares placebo and Levetiracetam groups, with 45.2% response in placebo (N=84) and 72.2% in Levetiracetam (N=79). An asterisk indicates statistical significance versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of Levetiracetam, showing a pyrrolidone ring with attached ethyl and amide functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.